SBRI funding: Clinical biomarker tools and technologies for dementia

Funding is available for innovations in dementia biomarker detection to transform clinical trials and precision therapies

Organisations can apply for a share of £6 million to develop or repurpose innovative solutions for dementia therapies. This is a Small Business Research Initiative (SBRI) competition funded by Innovate UK.

The aim of the competition is to accelerate innovations in dementia biomarker detection to transform the clinical development of precision therapies. These technologies will enable the discovery, validation and implementation of a suite of decision-enabling biomarkers.

Your project must:

• improve the sensitive detection of neurodegeneration, inflammation or vascular biomarkers associated with dementia
• advance the development of a novel biomarker platform or repurposed technology towards dementia indications
• describe how the technological solution would be implemented, including consideration of dementia patients, their carers and infrastructure and healthcare requirements
• consider diversity of patients to provide an accessible, equitable solution
• describe a credible and practical route to market, including manufacturing, health economic and regulatory considerations
• have a dedicated project manager

This is a single-phase competition. Any implementation of a solution from this competition would be subject to a separate procurement exercise.

Eligibility overview

Projects must:

• start on 1 December 2023
• end by 30 November 2024
• last between 6 months and 12 months
• have a dedicated project manager

To lead a project, you can:

• be an organisation of any size
• work alone or with other organisations as subcontractors

Find out more about the SBRI: Clinical biomarker tools and technologies for dementia competition.

First published 25 July 2023.